Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

NCT01356498 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
151
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Savient Pharmaceuticals